Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
about
Buprenorphine for treating cancer painTransdermal fentanyl for cancer painEmerging therapies for patients with symptoms of opioid-induced bowel dysfunction[Is the pharmacological treatment of constipation in palliative care evidence based? : a systematic literature review].Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceOpioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related painTransdermal buprenorphine - a critical appraisal of its role in pain management.Advances in pharmacotherapy for opioid-induced constipation - a systematic review.Extended-release opioids in the management of cancer pain: a systematic review of efficacy and safety.Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal SurgeriesDesign, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Methylnaltrexone for opioid-induced constipation: review and meta-analyses for objective plus subjective efficacy and safety outcomesManaging severe cancer pain: the role of transdermal buprenorphine: a systematic review.Critical illness, gastrointestinal complications, and medication therapy during enteral feeding in critically ill adult patients.Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations.The role of hydromorphone in cancer pain treatment: a systematic review.Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review.The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilitiesSafety and efficacy of transdermal buprenorphine for the relief of cancer pain.A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain.Alternative routes to oral opioid administration in palliative care: a review and clinical summary.Hydromorphone for cancer pain.Transdermal Buprenorphine Patches for Postoperative Pain Control in Abdominal SurgeryA feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain.Experimental dog model for assessment of fasting and postprandial fatty acid metabolism: pitfalls and feasibility.[Incidence of constipation in patients with outpatient opioid therapy].Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose.Methylnaltrexone: treatment for opioid-induced constipation--not convinced yet.Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery.Palliative care in ovarian carcinoma patients-a personalized approach of a team work: a review.
P2860
Q24187076-EA5F5E00-1D7A-44E4-80D5-BDA108A07A3CQ24197559-A8680995-5E6C-4CFE-9F33-50DC783C74E4Q27010907-CA81A2F1-CA21-4167-989D-FC24365026AEQ31104772-789579A0-D8EA-45DA-A5A8-60F3F87E5556Q33938740-FF2A296E-E6EB-4EAB-B0CC-7C3ADFA5C953Q34332179-FDE729BB-83B1-4207-801B-AC0F0D4F6C54Q34418193-FFB60B35-2774-4EF8-93E0-9208C15AC5B6Q34455604-11F90172-3A07-4B34-88D9-A636677D60E5Q35014155-35FC8CA3-1858-449F-A0C4-D9821E08972AQ36476375-681705E7-E02E-4B51-9912-C425DF86D11FQ36480105-96C11E4C-1537-4C1F-9480-AD203EBD9B5DQ36696556-D0E4F80F-1EE0-4C33-A79B-07646699753CQ37354641-6EACFABD-6092-4776-8831-16B41BC9A903Q37686927-9822FEDF-0028-4DE4-8604-8AC865E9851CQ37894990-9971A232-C83C-4131-A033-20CA281931BCQ37894993-7862566F-39C6-49DF-9291-2D66E98B6B25Q37894994-62C823E7-1B20-4092-AC69-79259ECBA2BEQ38116004-B99B0D64-792F-459D-A5CC-7F8F0322FCFAQ38127157-3E9DE915-1C82-4289-9991-5AFD43A48901Q38193819-6BDDC11E-9D7E-4E26-ABFE-0EFF5C8A8C4EQ38226298-540A0BBB-8434-44E7-BA99-4A7F9AD2562BQ38977999-79797C1D-D052-41D2-8C99-8E311BA85437Q39168922-036459AA-814B-49E5-B8D9-D17ED42DDD73Q39234435-EA813039-7F84-4281-B3E9-B53DA21E93CCQ41617827-CCECA68E-ACEE-4D22-AD7F-3A185B9E012FQ41637834-5596D483-7B98-47E1-A9BA-C3C7FA735BB3Q42614672-555110C0-D8AB-4699-9743-6FFEB06BD3CDQ44350120-4041B9FC-80FB-49CA-868B-727A5500127BQ47099470-C40B0889-3CB2-4BC5-A781-80F36FEF3168Q48248758-2C3FC708-2A35-4397-AABB-A4B72391CC41
P2860
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@en
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@nl
type
label
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@en
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@nl
prefLabel
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@en
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@nl
P2093
P2860
P1476
Gastrointestinal symptoms unde ...... and transdermal buprenorphine.
@en
P2093
Andreas Schroeck
Jens Standop
Joachim Nadstawek
Marcus Mueller
Maria Wittmann
Michael Schenk
Nico Schaefer
Norbert Kloecker
Stefan Wirz
P2860
P304
P356
10.1016/J.EJPAIN.2008.09.005
P577
2008-10-31T00:00:00Z